Asthma and lower airway diseasePhenotypic determinants of uncontrolled asthma
Section snippets
Population
This is a cross-sectional study using data from the case control and family-based EGEA2 study, the 12-year follow-up of the EGEA1 study. Protocol and descriptive characteristics of the EGEA1 study have been previously published.15, 16 Briefly, 2047 subjects were enrolled at baseline, including 388 children (<16 years) and adult patients with asthma from chest clinics, their 1244 first-degree relatives, and 415 population-based controls. Approximately 10 years later, this population was
Description of the population
Main personal, sociodemographic, and clinical characteristics of the population with asthma are presented in Table I. The mean age of the population was 39 years, and half of the subjects were nonsmokers and not exposed to tobacco smoke at the time of the survey. Regarding allergic phenotypes, 60.2% reported allergic rhinitis, 61.3% had total IgE ≥100 IU/mL, and 80.8% were sensitized to any of the 11 allergens. Chronic cough or phlegm was reported by 16% of the subjects. Patients with asthma
Discussion
Less than half (44%) of this population of patients with asthma participating in the phase 2 of the EGEA study had a controlled asthma, on the basis of characteristics of asthma control as defined in the current GINA guidelines. The proportion of controlled asthma was lower in ICS users, in whom only one fourth of the asthmatics had a controlled asthma. The determinants for uncontrolled asthma were different in ICS users and non-ICS users. In ICS users, chronic cough or phlegm and female sex
References (37)
- et al.
Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys
J Allergy Clin Immunol
(2004) - et al.
Asthma control in Europe: a real-world evaluation based on an international population-based study
J Allergy Clin Immunol
(2007) - et al.
Asthma control and differences in management practices across seven European countries
Respir Med
(2002) - et al.
Higher BMI is associated with worse asthma control and quality of life but not asthma severity
Respir Med
(2006) - et al.
Complexity of chronic asthma and chronic obstructive pulmonary disease: implications for risk assessment, and disease progression and control
Lancet
(2008) - et al.
Real-world Evaluation of Asthma Control and Treatment (REACT): findings from a national Web-based survey
J Allergy Clin Immunol
(2007) - et al.
Influence of patients' characteristics and disease management on asthma control
J Allergy Clin Immunol
(2006) - et al.
Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma
Respir Med
(2007) - et al.
Prognostic factors of asthma severity: a 9-year international prospective cohort study
J Allergy Clin Immunol
(2006) - et al.
Association between IgE levels and asthma severity among African American, Mexican, and Puerto Rican patients with asthma
J Allergy Clin Immunol
(2007)
Lack of association between indoor allergen sensitization and asthma morbidity in inner-city adults
J Allergy Clin Immunol
Persistent asthma: disease control, resource utilisation and direct costs
Eur Respir J
The control of asthma in Italy: a multicentre descriptive study on young adults with doctor diagnosed current asthma
Allergy
Lack of control of severe asthma is associated with co-existence of moderate-to-severe rhinitis
Allergy
Role of symptoms and lung function in determining asthma control in smokers with asthma
Allergy
Relationships of active smoking to asthma and asthma severity in the EGEA study. Epidemiological study on the Genetics and Environment of Asthma
Eur Respir J
Cited by (0)
Supported by grants from Merck Sharp & Dohme (MSD); Hospital program of clinical research (PHRC)-Paris; National Research Agency - Health environment, health-work program; National Research Agency (ANR)- Biological collections for health program; French Agency of health safety, environment and work (AFSSET) and the Isere committee against respiratory diseases (COMARES).
Disclosure of potential conflict of interest: C. Pison has served as a consultant for GlaxoSmithKline, Boehringer Ingelheim France, AstraZeneca, Nutricia, Numico, and Actéllion and has received research support from AB Science. The rest of the authors have declared that they have no conflict of interest.